Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

Rejoni, Inc., a privately held clinical-stage company based in Bedford, MA, dedicated to elevating uterine health through innovative biomaterial therapies, today announced the closing of a $25 million financing, with new and existing investors including ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital, and Sparta Group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616503636/en/

The proceeds will be used to build the foundation for the Juveena Hydrogel System, Rejoni’s first product. Juveena is designed to support endometrial healing within the uterine cavity following endometrial trauma associated with intrauterine surgery, a leading cause of intrauterine adhesions. Rejoni expects to scale manufacturing and supply operations, invest in market access, physician and patient engagement, and prepare for commercial launch of Juveena when approved by the U.S. FDA.

“Uterine health has been underserved for too long, and this financing puts us in a position to change that. We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved,” said John Nealon, Chief Executive Officer of Rejoni, Inc.